The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation pemetrexed, versus etoposidecisplatin and TRT followed by nonpemetrexed doublet consolidation therapy.
Patients and Methods
Patients with stage IIIA/B unresectable nonsquamous non-small-cell lung cancer randomly received (1:1) pemetrexed 500 mg/m 2 and cisplatin 75 mg/m 2 intravenously every 3 weeks for three cycles plus concurrent TRT (60 to 66 Gy) followed by pemetrexed consolidation every 3 weeks for four cycles (arm A), or standard therapy with etoposide 50 mg/m 2 and cisplatin 50 mg/m 2 intravenously, every 4 weeks for two cycles plus concurrent TRT (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B). The primary objective was OS. The study was designed as a superiority trial with 80% power to detect an OS hazard ratio of 0.74 with a type 1 error of .05.
INTRODUCTION
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, 1 and more than 25% of NSCLC is locally advanced disease.
2 Standard care for patients with inoperable stage III NSCLC with a good performance status (PS) is concurrent platinum-based doublet chemoradiotherapy. 3, 4 The ideal concurrent chemotherapy regimen has not been determined. 4 The two most commonly used regimens are etoposidecisplatin and carpoblatin-paclitaxel.
5, 6 The optimal radiation dose and schedule for concurrent treatment remains unclear, but standard doses range from 60 to 66 Gy. 3, 7, 8 Despite improvements in locoregional control and survival, a meta-analysis revealed that concurrent chemoradiation using older chemotherapy regimens in locally advanced NSCLC did not influence the rate of distant metastasis when compared with sequential chemoradiotherapy. inefficacious 10 ; thus, there is a demand for better management and more effective, less toxic chemoradiotherapy regimens.
Pemetrexed, a multitargeted antifolate, has selective activity in nonsquamous NSCLC 11 and has been shown to enhance radiation sensitivity in vitro. 12 Unlike other chemotherapy combinations, pemetrexed-cisplatin, a current standard of care for metastatic nonsquamous NSCLC, has a relatively well-tolerated safety profile when administered at full systemic dose with definitive thoracic radiation therapy (TRT). [13] [14] [15] [16] [17] [18] [19] [20] [21] In the metastatic setting, maintenance pemetrexed has shown a benefit in overall survival (OS) in nonsquamous NSCLC after completion of four cycles of first-line therapy. 22, 23 Pemetrexed has also been investigated in locally advanced NSCLC as consolidation therapy after pemetrexedplatinum-based chemoradiotherapy, with promising efficacy and safety results, 13, 15, 18, 19 suggesting that this regimen may have a systemic effect and, at systemically active chemotherapy doses, may reduce the risk of distant metastasis. Together, these factors formed the basis of this study design, which used concurrent pemetrexedcisplatin followed by consolidation pemetrexed.
The phase III PROCLAIM trial investigated whether pemetrexed-cisplatin with concurrent TRT followed by pemetrexed consolidation would produce superior survival compared with etoposide-cisplatin plus concurrent TRT followed by a nonpemetrexed consolidation treatment in stage IIIA/B NSCLC.
PATIENTS AND METHODS

Patients
Eligible patients were $ 18 years old with a histologically/cytologically confirmed diagnosis of nonsquamous NSCLC, stage IIIA/B disease without malignant pleural/pericardial effusion (supraclavicular nodal involvement was allowed), and an Eastern Cooperative Oncology Group PS of 0/1. Patients had a measurable lesion according to Response Evaluation Criteria in Solid Tumors v1.0, 24 or evaluable disease on computed tomography imaging and adequate organ and pulmonary function.
Patients were excluded if the radiation plan encompassed a volume of whole lung receiving $ 20 Gy (V 20 ) of more than 35% of lung volume or if they had had prior systemic chemotherapy for NSCLC. Study criteria details are available (Data Supplement).
This study protocol was approved by each institution's ethics review board and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before any study-related treatment or procedures commenced.
Study Design and Treatment
In this open-label study, eligible patients were stratified by baseline PS (0 v 1), sex (female v male), disease stage (IIIA v IIIB), and positron emission tomography (PET) scan (yes v no) and were randomly assigned (1:1) to one of two arms. Arm A received pemetrexed 500 mg/m 2 intravenously (IV) plus cisplatin 75 mg/m 2 IV every 3 weeks for three cycles and concurrent TRT followed by four cycles of consolidation pemetrexed 500 mg/m 2 IV every 3 weeks. Patients received premedication, including folic acid and vitamin B 12 , according to the pemetrexed label. 25 Arm B received etoposide 50 mg/m 2 IVon days 1 to 5 every 4 weeks followed by cisplatin 50 mg/m 2 on days 1 and 8 for two cycles plus concurrent TRT followed by two cycles of a platinum-based doublet regimen of choice as consolidation treatment: etoposide-cisplatin (same dose and schedule as during concurrent treatment) or vinorelbine 30 mg/m 2 IV on days 1 and 8 every 3 weeks and cisplatin on day 1 every 3 weeks (vinorelbine-cisplatin) or paclitaxel 200 mg/m 2 IV every 3 weeks followed by carboplatin IV (area under the concentration-time curve, 6) every 3 weeks (paclitaxel-carboplatin).
Concurrent TRT, 2 Gy/fraction daily/5 days per week to a target dose of 60 to 66 Gy in 30 to 33 fractions, started on day 1 of chemotherapy. No field reductions were permitted during radiotherapy, and the entire planning treatment volume (PTV; $ 95% of PTV receiving $ 93% of prescription dose) was treated daily. Radiation quality assurance is described (Data Supplement).
Standard chemotherapy dose adjustments applied. Treatment-related grade 3 radiation pneumonitis and TRT interruptions greater than 7 days because of intercurrent illness required discontinuation. To begin consolidation chemotherapy, all previous nonhematologic toxicities, except neuropathy, had to be resolved to grade # 2. (Data Supplement).
Baseline and Treatment Assessments
Baseline tumor assessments were performed within 28 days before the start of treatment. Assessments were repeated at the end of concurrent treatment, before consolidation, and during follow-up according to the study schedule (Data Supplement).
All patients who received at least one dose of chemotherapy were evaluated for safety and assessed for toxicity before each cycle using the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.
26 Analyses of OS (primary end point) and progression-free survival (PFS; secondary end point) were conducted on the intent-to-treat (ITT) population. OS was measured from the date of random assignment to the date of death as a result of any cause. For each patient who was not known to have died as of the data lock date, OS was censored at the date the patient was last known to be alive. PFS was defined as the time from the date of random assignment to the first date of documented objective progressive disease or death as a result of any cause. For each patient who was not known to have died or to have had objective progressive disease as of the data lock date, PFS was censored at the date of the last objective progression-free disease assessment. For patients who took subsequent systemic anticancer therapy before disease progression or death, PFS was censored at the date of the last objective progression-free disease assessment before the date of the subsequent systemic anticancer therapy.
Secondary end points included tumor response rates; 1-, 2-, and 3-year survival rates; and assessment of the first disease failure sites. Disease control rate (DCR), defined per treatment arm as the proportion of randomly assigned patients having a confirmed best objective response of stable disease, partial response, or complete response multiplied by 100, was also assessed.
Statistical Analyses
Approximately 600 patients were planned to be randomly assigned in this superiority trial on a 1:1 basis, assuming a minimum of 355 deaths with 80% power to detect a hazard ratio (HR) of 0.74 (arm A v arm B) with a two-sided a level of .05 for the standard log-rank test.
OS and PFS were estimated using the Kaplan-Meier method. 27 HRs were estimated using Cox proportional hazards models.
28 A Cox regression model was used to determine treatment effect on OS and PFS after adjusting for potential prognostic variables. The percent of patients with first site of disease failure was compared between arms using Fisher's exact test. Objective tumor response rates were compared between treatment arms using an unadjusted, normal distribution approximation for the difference in rates. A 95% CI for response rate of each arm was calculated using an exact method. Adverse events (AEs) were compared using Fisher's exact test.
An independent data monitoring committee evaluated unblinded safety information 6 months after the first 100 patients and then after all patients completed consolidation chemotherapy. Efficacy (futility) was evaluated by the data monitoring committee after 165 deaths had occurred to assess the merits of continuing patient enrollment. The trial was to be stopped for futility if the one-sided log-rank P value was greater than .5, corresponding approximately to an observed HR of 1.00 under an exponential model.
All statistical analyses were performed using the software SAS version 9.2 (SAS Institute, Cary, NC).
An interim analysis, performed in July 2012, occurred after 173 deaths and included data from 552 randomly assigned patients. Patient enrollment (n = 598) was terminated for futility before reaching the accrual target of 600 patients. No new safety concerns were identified during the study; therefore, patients were permitted to continue their assigned study therapy.
Patient Characteristics
Between October 20, 2008, and August 31, 2012, 125 institutions in 21 countries screened 932 patients for entry; 334 patients were not randomly assigned. The remaining 598 patients were randomly assigned (301, arm A; 297, arm B) and comprised the ITT population. Forty-three randomly assigned patients (18, arm A; 25, arm B) were not treated (largely because of unmet protocol entry criteria and patient/physician decision), leaving 555 patients (283, arm A; 272, arm B) eligible for concurrent treatment (Fig 1) . Baseline patient and disease characteristics were well balanced and reflected the target population (Table 1) . Patients with supraclavicular node involvement were included (arm A, 20 [6.6%]; arm B, 19 [6.4%] ). Median follow-up times for all patients were 22.2 months (arm A) and 22.6 months (arm B) at final data lock and 32.9 and 35.7 months, respectively, for alive patients.
Treatment
Of 283 patients who began treatment with pemetrexed and cisplatin (arm A) in the concurrent phase, 229 patients (80.9%) completed concurrent treatment as planned and received at least one dose of pemetrexed in the consolidation phase. Of 272 patients who began treatment with etoposide and cisplatin (arm B) in the concurrent phase, 202 patients (74.3%) completed concurrent treatment and received at least one dose of a platinum doublet regimen in the consolidation phase (Appendix Table A1 , online only). The most frequent reason for discontinuation from concurrent treatment was AEs (arm A, 5.7%; arm B, 8.1%; Fig 1) .
Overall study compliance, measured by the percentage of patients who completed both treatment phases per protocol, was 58.0% in arm A and 62.1% in arm B.
Delivered dose intensities were similar for both arms during concurrent treatment (arm A, 96.0% pemetrexed and 95.9% cisplatin; arm B, 97.0% etoposide and 94.9% cisplatin) and numerically higher in arm A during consolidation treatment (95.4% pemetrexed) than in arm B (92.6% etoposide-cisplatin, 87.5% vinorelbine-cisplatin, 90.7% paclitaxel-carboplatin; Appendix Tables A1 and A2, online only). A smaller percentage of patients in arm A required dose adjustment, including dose reductions and dose omissions during both treatment phases (Appendix Table A3 , online only).
Exposure to TRT was similar between arms (total mean [6SD] dose [Gy], 63.2 6 7.1, arm A; 61.9 6 10.5, arm B; Appendix Table A4 , online only). Similar percentages of patients in each arm received between 60 and 66 Gy (93.3%, arm A; 91.9%, arm B) or less than 60 Gy (6.0%, arm A; 8.1%, arm B) radiotherapy. A smaller percentage of patients in arm A than in arm B (7.8% and 11.4%, respectively) had radiotherapy dose interruptions during the concurrent phase.
Efficacy
OS (Fig 2A) in arm A was not significantly longer than in arm B (HR, 0.98; 95% CI, 0.79 to 1.20; log-rank P = .831; median, 26.8 v 25.0 months). One-, 2-, and 3-year OS rates were not significantly different for arm A versus arm B (76% v 77%, 52% v 52%, and 40% v 37%, respectively). The censoring rates were 41.2% (arm A) and 39.4% (arm B). Fig 2B) was 1.6 months longer in arm A than in arm B, but this increase was not statistically significant (HR, 0.86; 95% CI, 0.71 to 1.04; log-rank P = .130; median, 11.4 v 9.8 months).
PFS (
The objective response rate was not statistically different between arms (35.9% in arm A v 33.0% in arm B). The DCR was significantly higher in arm A compared with that in arm B (80.7% v 70.7%), although it was not a protocol-specified end point (Table 2) .
A smaller, but not statistically significant, percentage of patients had first relapse within the radiation treatment field (37.3%, arm A; 45.8%, arm B). A similar percentage of patients in each arm had a distant relapse (50.0%, arm A; 45.8%, arm B) and/or brain metastasis (18.7%, arm A; 19.5%, arm B; Table 3 ).
Prespecified subgroup analyses (Fig 3) revealed a treatment effect across subgroups similar to that observed in the primary analysis of OS and PFS in the ITT population. In two subgroups, patients with the highest PTVs (. 700 mL) and stage IIIB disease, pemetrexed-cisplatin tended to provide a greater treatment benefit for PFS (HR, 0.79; 95% CI, 0.55 to 1.13; HR, 0.76; 95% CI, 0.58 to 0.98, respectively).
Safety
Treatment-emergent AEs possibly related to study treatment during the overall study (protocol therapy and follow-up) and concurrent phase are listed in Table 4 . During the overall study, the incidence of any grade 3 to 4 events was significantly lower in arm A than in arm B (64.0% v 76.8%, P = .001). Thrombocytopenia (any grade) and neutropenia (any grade and grade 3 to 4) occurred significantly less frequently in arm A than in arm B (19.4% v 31.3%, P = .002; 42.8% v 54.8%, P = .005; 24.4% v 44.5%, P ,.001, respectively). Pneumonitis (any grade and grade 2) was significantly higher in arm A than in arm B (17.0% v 10.7%, P = .37; 11.0% v 5.5%, P = .021, respectively). In the concurrent phase, the incidence of grade 3 to 4 neutropenia and febrile neutropenia was significantly lower in arm A than in arm B (18.4% v 28.7%, P = .005; 3.2% v 7.4%, P = .035, respectively), and pneumonitis was low in both treatment arms. In addition to esophagitis, febrile neutropenia was the only other treatment-related serious AE that occurred in $ 5% of treated patients (4.2% in arm A v 8.5% in arm B, P = .054). There were no significant differences between arms in discontinuations because of possibly drug-related AEs (11.0% in arm A v 8.8% in arm B) or possibly drug-related deaths (five [1.8%] in arm A v three [1.1%] in arm B).
The eight treatment-related AEs that led to death are as follows: for arm A, acute respiratory failure, pulmonary hemorrhage, cardiorespiratory arrest, pneumonia, and neutropenic sepsis, and arm Kaplan-Meier estimates of (A) overall survival (OS; primary end point) in the intent-totreat (ITT) population and (B) progression-free survival (PFS) in the ITT population. OS was measured from the date of random assignment to the date of death as a result of any cause. At the cutoff date for data inclusion in the analysis, if a patient had not died, OS was censored at the last date they were known to still be alive. PFS was measured from the date of random assignment to the first date of documented objective progression of disease or of death as a result of any cause. PFS was censored at the date of the last objective progression-free disease assessment before the date of any subsequent systemic anticancer therapy or death, whichever applied first. Eto-Cis, etoposide-cisplatin; HR, hazard ratio; Pem-Cis, pemetrexed-cisplatin.
B, respiratory failure, aspiration, and hypovolemic shock. Two deaths, possibly related to treatment, occurred in arm A within 30 days of study discontinuation because of respiratory failure and pneumonitis.
Postdiscontinuation Therapy
Similar percentages of patients received postdiscontinuation anticancer therapy (42.5%, arm A; 49.2%, arm B), including systemic therapy (33.2%, arm A; 36.0%, arm B), palliative radiotherapy (20.3%, arm A; 27.9%, arm B), or surgery (7.0%, arm A; 8.4%, arm B). Systemic therapy use was similar between arms, except for pemetrexed, which was higher in arm B (21.5%) than in arm A (8.6%), and the selection of platinum (cisplatin: 9.3%, arm A; 7.4%, arm B; carboplatin: 7.0%, arm A; 9.8%, arm B).
DISCUSSION
In this trial, pemetrexed-cisplatin plus concurrent TRT followed by consolidation pemetrexed did not improve OS compared with etoposide-cisplatin plus concurrent TRT followed by consolidation therapy with a non-pemetrexed-platinum doublet. The median survival times were not significantly different between arms A and B; both arms achieved higher median survival times (. 5 months) than anticipated on the basis of historical data, 10,29-31 including a systematic review of 32 published trials of etoposide-cisplatin administered concurrently with TRT. 6 However, the observed OS in PROCLAIM was in the same range as that reported in the RTOG 0617 trial, 7 possibly reflecting higher use of staging PET scans in both trials (. 81% of patients). The evidence of the significant impact of PET staging on survival outcomes because of stage migration is well documented. 32, 33 Future analyses will explore the stage migration effect on survival outcomes, including 3-year survival, in the subgroup of patients who underwent a staging PET scan (n = 491), compared with those who did not (n = 107).
Investigator-assessed PFS trended in favor of the pemetrexedcisplatin arm, and the relative treatment effect was consistent across subgroups and similar to that observed in the unadjusted analysis of PFS. In addition, patients with stage IIIB disease and higher PTV (. 700 mL), two characteristics generally associated with poorer survival outcomes, 31 trended to a higher OS benefit from the pemetrexed regimen, indicating the need for further investigation of pemetrexed-cisplatin in patients with larger tumors.
Although the objective response rate was comparable between treatment arms, DCR was high in both arms and it improved significantly in arm A compared with arm B on the basis of a higher percentage of stabilizations and fewer progressions as best response during treatment. The higher number of stabilizations than responses in this study may be related to the fact that approximately 50% of randomly assigned patients had stage IIIB NOTE. Tumor response was assessed using RECIST v1.0. 24 The P value is based on unadjusted, normal distribution approximation for the difference in rates. The 95% CIs for ORR and DCR are based on an exact method Abbreviations: CR, complete response; DCR, disease control rate; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease. *Unknown response on the basis of RECIST, could not be determined because of incomplete postbaseline lesion data. †Not performed because no baseline measurements were provided (patients randomly assigned but not treated) or because no postbaseline assessment was available. ‡Defined as the proportion of PR or CR multiplied by 100. §Defined as the proportion of SD, PR, or CR multiplied by 100. NOTE. P values are based on Fisher's exact test; 95% CI was based on an exact method. Study arms included all randomly assigned patients with objective progressive disease. All responses were physician scored and not centrally reviewed. Pathologic confirmation of recurrence was not mandatory. *Some patients (approximately 8%) relapsed in more than one site.
disease and nearly 30% for whom data were available had high PTVs (. 700 mL). The incidence of possible treatment-related grade 3 to 4 events during the study was significantly lower in arm A. Concurrent treatment toxicities were generally consistent with overall study toxicities. In arm A, the incidence of grade 3 to 4 neutropenia across all treatment phases and febrile neutropenia during concurrent treatment were significantly lower than in arm B. The tolerability of concurrent chemoradiotherapy with pemetrexedcisplatin was supported by the lower incidence of dose adjustments in arm A than in arm B, and a higher percentage of patients in arm A who completed concurrent treatment as planned and received www.jco.org consolidation treatment. This is in contrast to the East Asian KCSG-LU05-04 trial, in which approximately one-third of the patients who received concurrent chemoradiotherapy with docetaxel-cisplatin did not receive consolidation chemotherapy with the same chemotherapy regimen. 34 The incidence of any grade pneumonitis in PROCLAIM was significantly higher in arm A because of grade 2 events, whereas grade 3 to 4 events were observed in less than 3% of patients in both arms. Similar low incidences of grades 3 to 4 radiation pneumonitis were reported in the RTOG 0617 and KCSG-LU05-04 trials. 7, 34 Local relapse occurred in 37.3% and 20.5% of patients within and outside (but still within the thorax) of the radiation field in arm A of PROCLAIM, respectively. There was a similar pattern of local and distant relapse in PROCLAIM and the standard arm of the RTOG 0617. 7 The PROCLAIM study did not generate mature 5-year survival data because the protocol-specified follow-up period was 3 years.
In conclusion, the PROCLAIM trial did not demonstrate superior OS for pemetrexed-cisplatin with pemetrexed consolidation compared with etoposide-cisplatin plus consolidation therapy, in keeping with early stopping of enrollment for futility. A significantly lower incidence of drug-related grade 3 to 4 AEs, including neutropenia, was observed during the overall study period for pemetrexed-cisplatin. Grade 3 to 4 neutropenia and febrile neutropenia were also lower for pemetrexed-cisplatin during concurrent therapy. The PROCLAIM trial showed that NOTE. Treatment-emergent adverse events refers to any untoward medical occurrence that occurs or worsens at any time after treatment baseline and that does not necessarily have to have a causal relationship with this treatment. Treatment-related events include those with a causal relationship to either chemotherapy, radiotherapy, or both. Adverse events were graded in accordance with CTCAE v3.0 and Medical Dictionary for Regulatory Activities v17.1. Bold data indicate a significant P value (, .05) on the basis of Fisher's exact test. Abbreviations: AGC, absolute granulocyte count; ANC, absolute neutrophil count; CTCAE, Common Terminology Criteria for Adverse Events; Gr, grade; WBC, white blood cells. *Possible study treatment-related grade 5 events in arm A for the overall study included three events (one febrile neutropenia and two pneumonitis), whereas in arm B, one patient experienced two grade 5 events (one febrile neutropenia and one renal failure). †Possible study treatment-related grade 5 events in arm A during the concurrent phase included one patient with one event (febrile neutropenia), and in arm B, one patient experienced two grade 5 events (febrile neutropenia and renal failure).
‡Combined term.
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GLOSSARY TERMS
cisplatin: an inorganic platinum agent (cisdiamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. Carboplatin and oxaliplatin are other members of this class.
non-small-cell lung cancer (NSCLC): a type of lung cancer that includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma.
overall survival: the duration between random assignment and death.
progression-free survival: time from random assignment until death or first documented relapse, categorized as either locoregional (primary site or regional nodes) failure or distant metastasis or death. Abbreviations: IMRT, intensity-modulated radiotherapy; PTV, planned treatment volume; SD, standard deviation; TRT, thoracic radiation therapy; V 5 , volume of whole lung minus PTV receiving $ 5 Gy of radiation expressed as a percent; V 20 , volume of whole lung minus PTV receiving $ 20 Gy of radiation expressed as a percent.
